/AGTX
AGTX Stock - Agentix Corp.
Healthcare|BiotechnologyOTC
$0.04-4.65%
$0.00 (-4.65%) • Dec 19
64
GoAI Score
GoAI Score
Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.HOLD
Medium Confidence
Momentum
Momentum Score
Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.37
Sentiment
Sentiment Score
Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).70
Risk Score
Risk Score
Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.100
Price Target
Price Target
Average analyst price target from the last quarter. Shows expected upside/downside from current price.+10.0%upside
Target: $0.05
AI Analysis PreviewPremium
Real-time AI-powered market analysis
Precise entry/exit price targets
Risk assessment & position sizing
Unlock GoAI Insights for AGTX
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Buy/Sell Signals
94% win rate on Alpha signals
Deep Analysis
Institutional-grade thesis
Real-Time Alerts
SMS & push notifications
Risk Scoring
Multi-factor analysis
Free 14-day trial • No credit card required
Active Trade Setup
ENTRY ZONE$0.04 – $0.04
TARGET (TP)$0.05
STOP LOSS$0.04
RISK/REWARD1:9.0
Premium members get real-time SMS alerts
Price Chart
Financial Statements
Revenue & Profitability Trend
← Swipe to see more →
Revenue
Net Income (Profit)
Net Loss
Key Metrics
Market CapN/A
P/E RatioN/A
Beta0.49
52W High$0.20
52W Low$0.02
Avg VolumeN/A
Income Statement (Fiscal Year)
| Metric | FY2025 | FY2023 | FY2021 | FY2019 | FY2018 |
|---|---|---|---|---|---|
| Revenue | N/A | N/A | $1,240 | N/A | N/A |
| Gross Profit | N/A | N/A | $679 | N/A | N/A |
| Gross Margin | N/A | N/A | 54.8% | N/A | N/A |
| Operating Income | $-513,251 | $-1,371,756 | $-1,341,031 | $-121,317 | $-134,376 |
| Net Income | $-567,048 | $-1,374,211 | $-1,340,347 | $-143,987 | $-85,418,706 |
| Net Margin | N/A | N/A | -108092.5% | N/A | N/A |
| EPS | $-0.01 | $-0.04 | $-0.39 | $-0.07 | $-7736.50 |
Company Overview
Agentix Corp., a clinical development stage company, focuses on the development and commercialization of therapeutics to treat metabolic diseases. Its product pipeline includes AGTX-2004, a peripherally-acting CB1 receptor antagonist that has demonstrated efficacy in animal models of obesity and type 2 diabetes mellitus; and AGTX-2003, a peripherally-acting CB1 receptor inverse agonist, which has demonstrated efficacy in animal models of obesity and non-alcoholic fatty liver diseases. The company was formerly known as FairWind Energy, Inc. and changed its name to Agentix Corp. in June 2019. Agentix Corp. was incorporated in 2013 and is based in Dana Point, California.
Visit WebsiteLoading analyst ratings...
Earnings History & Surprises
AGTXBeat Rate
0%
Last 0 quarters
Avg Surprise
+0%
EPS vs Estimate
Beats / Misses
0/0
Last 12 quarters
Latest EPS
$-0.00
Q4 2025
EPS Surprise History
Q1 22
No data
Q2 22
No data
Q3 22
No data
Q4 22
No data
Q1 23
No data
Q3 23
No data
Q3 23
No data
Q4 25
No data
Beat Estimate
Missed Estimate
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q1 2026 | Feb 16, 2026 | — | — | — | — |
Q4 2025 | Nov 17, 2025 | — | $-0.00 | — | — |
Q3 2025 | Aug 28, 2025 | — | — | — | — |
Q1 2025 | Feb 18, 2025 | — | — | — | — |
Q4 2024 | Nov 18, 2024 | — | — | — | — |
Q3 2024 | Aug 30, 2024 | — | — | — | — |
Q3 2024 | Aug 1, 2024 | — | — | — | — |
Q1 2024 | Feb 14, 2024 | — | — | — | — |
Q4 2023 | Nov 20, 2023 | — | — | — | — |
Q3 2023 | Aug 22, 2023 | — | $-0.01 | — | — |
Q3 2023 | Jul 13, 2023 | — | $-0.01 | — | — |
Q1 2023 | Feb 14, 2023 | — | $-0.01 | — | — |
Q4 2022 | Nov 14, 2022 | — | $-0.01 | — | — |
Q3 2022 | Aug 11, 2022 | — | $-0.00 | — | — |
Q2 2022 | Apr 13, 2022 | — | $-0.05 | — | — |
Q1 2022 | Jan 13, 2022 | — | $-0.01 | — | — |
Q4 2021 | Oct 7, 2021 | — | $-0.01 | — | — |
Q3 2021 | Jul 9, 2021 | — | $-0.00 | — | — |
Q1 2021 | Mar 29, 2021 | — | $-0.02 | — | — |
Q1 2021 | Jan 13, 2021 | — | $-0.01 | — | — |
Latest News
Loading news...
Frequently Asked Questions about AGTX
What is AGTX's current stock price?
Agentix Corp. (AGTX) is currently trading at $0.04 per share. The stock has moved -4.65% today.
What is the analyst price target for AGTX?
No analyst price targets are currently available for this stock.
What sector is Agentix Corp. in?
Agentix Corp. operates in the Healthcare sector, specifically within the Biotechnology industry. The company is traded on the OTC exchange.
What is AGTX's market cap?
Agentix Corp. has a market capitalization of $0.00 billion, making it a small-cap company.
Does AGTX pay dividends?
No, Agentix Corp. does not currently pay a dividend to shareholders.
Similar Stocks
Healthcare SectorAGNPF
Algernon Pharmaceuticals Inc.
$0.06
Mkt Cap: $0.0B
APLIF
Appili Therapeutics Inc.
$0.02
Mkt Cap: $0.0B
EBYH
Strainsforpains, Inc.
$0.16
Mkt Cap: $0.0B
GRTX
Galera Therapeutics, Inc.
$0.02
Mkt Cap: $0.0B
HESG
Health Sciences Group, Inc.
$0.00
Mkt Cap: $0.0B
IBOGF
Universal Ibogaine Inc.
$0.01
Mkt Cap: $0.0B
MDGEF
Medigene AG
$2.59
Mkt Cap: $0.0B
NBCO
Neon Bloom, Inc.
$0.01
Mkt Cap: $0.0B
NMLSF
Restart Life Sciences Corp.
$0.08
Mkt Cap: $0.0B
STMM
Stemcell Holdings, Inc.
$0.06
Mkt Cap: $0.0B
Explore stocks similar to AGTX for comparison